Total Synthesis of (±)-Lepadiformine via an Amidoacrolein Cycloaddition

T. J. Greshock and Raymond L. Funk*

Department of Chemistry, Pennsylvania State University, University Park, Pennsylvania 16802

rlf@chem.psu.edu

Received August 15, 2001

ABSTRACT



The total synthesis of the cytotoxin lepadiformine is described. The intermolecular cycloaddition of a 2-amidoacrolein with the dimethyl acetal of 4,6-heptadienal gave a cycloadduct that was strategically functionalized for elaboration of the tricyclic ring system. These steps include a diastereoselective addition of an organoytterbium reagent to an aldehyde, cyclization to the *trans*-perhydroquinoline substructure via a Mitsunobu reaction, and an iodine-promoted amine cyclization with an alkene to introduce the pyrrolidine ring.

Several structurally intriguing and biologically active tricyclic alkaloids were discovered in the mid-1990s and include the cytotoxins lepadiformine,¹ fasicularin,² cylindricines A/B,³ and the immunosuppressent FR901483.⁴ Not surprisingly, numerous groups have undertaken total syntheses of these novel structures.⁵ Our interest in these natural products emanated from methodology we had developed for the preparation of the simplest common substructure among these natural products, namely, a 1-alkyl-1-aminocyclohexane. Specifically, we have prepared this central subunit via Diels–

Alder cycloaddition reactions of 2-amidoacroleins with dienes, work which culminated in the total synthesis of FR901483.^{5h} We now wish to report on the further application of this basic strategy in the total synthesis of (\pm) -lepadiformine.

Several groups contributed to the structural elucidation of lepadiformine. Thus, lepadiformine was isolated by Biard and co-workers from the tunicate *Clavelina lepadiformis* and assigned the rather unusual zwitterionic structure (Figure 1) primarily on the basis of extensive NMR experiments,¹ although the absolute configuration of lepadiformine was not determined. However, Weinreb and co-workers synthesized the structure assigned to lepadiformine and found that the synthetic material was not identical with the natural product, nor did it exist in a zwitterionic form.⁶ Moreover, Pearson and co-workers synthesized three of the four diastereomers of lepadiformine at C(2) and C(13) and found them to be different from lepadiformine.⁷ They speculated that lepadiformine was epimeric at C(10) and possessed a *trans*-perhydroquinoline substructure like fasicularin.^{7b} This con-

⁽¹⁾ Biard, J. F.; Guyot, S.; Roussakis, C.; Verbist, J. F.; Vercauteren, J.; Weber, J. F.; Boukef, K. *Tetrahedron Lett.* **1994**, *35*, 2691.

⁽²⁾ Patil, A. D.; Freyer, A. J.; Reichwein, R.; Carte, B.; Killmer, L. B.; Faucette, L.; Johnson, R. K. *Tetrahedron Lett.* **1997**, *38*, 363.

^{(3) (}a) Blackman, A. J.; Li, C.; Hockless, D. C. R.; Skelton, B. W.; White, A. H. *Tetrahedron* **1993**, *49*, 8645. (b) Li, C.; Blackman, A. J. *Aust. J. Chem.* **1994**, *47*, 1355. (c) Li, C.; Blackman, A. J. *Aust. J. Chem.* **1995**, *48*, 955.

⁽⁴⁾ Sakamoto, K.; Tsujii, E.; Abe, F.; Nakanishi, T.; Yamashita, M.; Shigematsu, N.; Izumi, S.; Okuhara, M. J. Antibiot. **1996**, 49, 37.

⁽⁵⁾ For completed total syntheses of lepadiformine and fasicularin, see: (a) Abe, H.; Aoyagi, S.; Kibayashi, D. J. Am. Chem. Soc. **2000**, 122, 4583. For cylindricines, see: (b) Snider, B. B.; Liu, T. J. Org. Chem. **1997**, 62, 5630. (c) Molander, G. A.; Rönn, M. J. Org. Chem. **1999**, 64, 5183. (d) Liu, J. F.; Heathcock, C. H. J. Org. Chem. **1999**, 64, 8263. For FR901483, see: (e) Snider, B. B.; Lin, H. J. Am. Chem. Soc. **1999**, 121, 7778. (f) Scheffler, G.; Seike, H.; Sorensen, E. J. Angew. Chem., Int. Ed. **2000**, 39, 4593. (g) Ousmer, M.; Braun, N. A.; Ciufolini, M. A. Org. Lett. **2001**, 3, 765. (h) Funk, R. L.; Maeng, J. H. Org. Lett. **2001**, 3, 1125.

^{(6) (}a) Werner, K. M.; De los Santos, J. M.; Weinreb, S. M.; Shang, M. J. Org. Chem. **1999**, 64, 686. (b) Werner, K. M.; De los Santos, J. M.; Weinreb, S. M.; Shang, M. J. Org. Chem. **1999**, 64, 4865.

^{(7) (}a) Pearson, W. H.; Barta, N. S.; Kampf, J. W. *Tetrahedron Lett.* **1997**, *38*, 3369. (b) Pearson, W. H.; Ren, Y. J. Org. Chem. **1999**, *64*, 688.



jecture was confirmed by Kibayashi and co-workers, who reported the total synthesis of the revised structure shown in Figure 1 and discovered that the corresponding hydrochloride salt was identical to the natural product.^{5a} This structure was unambiguously determined on the basis of X-ray crystallographic analysis, which also showed that the *trans*-perhydroisoquinoline substructure prefers to adopt a chair-boat conformation.⁸ Parenthetically we note that these combined efforts signify the continuing value of contemporary organic synthesis in natural product structure determinations.

We were intrigued to learn that lepadiformine embodies a *trans*- rather than *cis*-perhydroisoquinoline subunit as found in the cylindricines, since the former stereochemistry is more accessible using our amidoacrolein-cycloaddition-based methodology. In our retrosynthetic analysis (Scheme 1), we



envisaged the pyrrolidine ring of lepadiformine (1) to arise from a stereoselective electrophile-promoted cyclization of the amine derived from tosylamide 2 with the angular

⁽⁸⁾ This is likely the solution structure as well. Molecular mechanics calculations (MMX, PCMODEL) place the chair-chair conformer 4.7 kcal/ mol higher in energy than the chair-boat conformer shown in Figure 1.





3-butenyl substituent.⁹ The hexyl substituent of sulfonamide **2** could be introduced by stereoelectronically controlled¹⁰ addition (α via chair vs. β via boat) of an organometallic reagent to the *N*-tosyl- (or *N*-acyl-) iminium ion **3**. The butenyl substituent of **3** could be elaborated by addition of an allylic organometallic reagent to the activated aziridine **4**, in turn, available by Mitsunobu ring closure of the debenzylated derivative of the tosylamide **5**. Finally, tosylamide **5** could be prepared by straightforward application of our methodology, namely, a regio- and *endo*-selective cycloaddition of the amidoacrolein **6** with the diene **7**, thereby establishing the eventual *trans*-perhydroquinoline stereochemistry.

To that end, the amidoacrolein **6** was prepared using our standard protocol. Thus, 2,2-dimethyl-1,3-dioxin-5-one¹¹ (**8**) was condensed with benzylamine to afford the corresponding imine, which was sulfonylated with tosyl chloride to furnish the desired 5-amido-1,3-dioxin **9**. Retrocycloaddition of dioxin **9** in refluxing toluene gave the amidoacrolein **6** in nearly quantitative yield, which when subjected to diene **7**¹² under the influence of high pressure (12 kbar) gave only the

⁽⁹⁾ For reviews, see: (a) Bartlett, P. A. in *Asymmetric Synthesis*; Morrison, J. D., Ed.; Academic Press: Orlando, FL, 1984; Vol. 3, p 411.
(b) Frederickson, M.; Grigg, R. *Org. Prep. Proced. Int.* **1997**, *29*, 33. (c) Frederickson, M.; Grigg, R. *Org. Prep. Proced. Int.* **1997**, *29*, 63.

⁽¹⁰⁾ For reviews, see: (a) Stevens, R. V. Acc. Chem. Res. **1984**, 17, 289. (b) Deslongchamps, P. Stereoelectronic Effects in Organic Chemistry; Pergamon Press: New York, 1983; p 209.

⁽¹¹⁾ Prepared in two steps from tris(hydroxymethyl)aminomethane hydrochloride. Hoppe, D.; Schmincke, H.; Kleemann, H.-W. *Tetrahedron* **1989**, 45, 687.

⁽¹²⁾ Prepared from 4,6-heptadienenitrile (Grieco, P. A.; Larsen, S. D. J. Org. Chem. **1985**, *50*, 1768) by DIBALH reduction (CH₂Cl₂, -60 °C, 88%) and acetalization of the resulting aldehyde (trimethyl orthoformate, amberlyst 15 ion-exchange resin, 12 h, rt, 98%).

endo cycloadduct **10** (74%).¹³ The aldehyde functionality of **10** was reduced (NaBH₄) followed by simultaneous debenzylation and reduction of the alkene moiety (Pearlman's catalyst, H₂) to furnish an alcohol that underwent a Mitsunobu-type ring closure to *N*-tosylaziridine **4** upon treatment with triphenylphosphine, iodine, and imidazole. Finally, the butenyl group of tosylamide **11** was installed by nucleophilic ring opening of *N*-tosylaziridine **4** with excess allylmagnesium bromide.

We had intended to introduce the hexyl substituent of lepadiformine by subjecting α -methoxytosylamide **12** to BF₃ in the presence of a hexyl Grignard or cuprate reagent.¹⁴ However, all attempts to cyclize acetal **11** to α -methoxytosylamide **12** using a variety of acid catalysts were unsuccessful and in many cases afforded the enamide **13** (BF₃, 0.5 h, 0 °C, 98%). Moreover, aldehyde **16** (Scheme 3), which could



be prepared by hydrolysis of acetal **11** (1 M HCl, H₂O, THF, 2 h, 98%), showed no tendency to exist in the cyclic α -hydroxytosylamide form in a variety of solvents (¹H NMR) and could not be converted to α -methoxytosylamide **12**.¹⁵

Accordingly, we turned to generating tosyliminium ion **3** by protonation of enamide **13** and its interception by an allylsilane.^{14–16} Indeed, we were pleased to find that treatment of enamide **13** with 4 equiv of trifluoroacetic acid and 6 equiv of allyltrimethylsilane (**14**, R = H) in methylene chloride at -20 °C gave a single product to which we assigned structure **15** on the basis of the aforementioned stereoelectronic

considerations¹⁰ and spectral similarities with tosylamide **2** (vide infra). Unfortunately, all attempts to employ (3-hexenyl)trimethylsilane (**14**, R = Pr)¹⁷ in this transformation gave only recovered enamide **13**.¹⁸

We also examined an alternative approach to the fully substituted trans-perhydroquinoline ring system concurrent with the previously discussed tosyliminium ion strategy, specifically, stereoselective introduction of the hexyl group prior to ring closure (Scheme 3). Initial experiments were not encouraging. For example, treatment of aldehyde 16 with hexylmagnesium bromide (5 equiv, -78 °C) in THF gave 18 and its inseparable C(13) epimer in a ratio of 1.1:1, respectively, and an even less desirable ratio (1:2.7) was obtained using hex₂CuLi in ether. The stereoselectivity was improved somewhat (2.5:1) by using hexylmagnesium bromide (5 equiv) in ether and, interestingly, even further if THF (10 equiv) was added (4.1:1). However, the most dramatic improvement (10.9:1) was observed when an organoytterbium reagent was employed following the Molander protocol¹⁹ (3 equiv of hexMgBr, 3 equiv of Yb(OTf)₃, THF, -78 °C; an inferior ratio of 3.4:1 was obtained if hexyllithium was used to prepare the organoytterbium reagent). We tentatively rationalize this stereoselectivity on the basis of the chelation control depicted in structure 17.²⁰ The superiority of the organoytterbium reagent may be a consequence of its greater steric bulk as well as attenuated reactivity with a magnesium-chelated aldehyde (slow disappearance of aldehyde 16 with the organoytterbium reagent versus instantaneous disappearance with the Grignard reagent).

The stereochemical assignment for alcohol 18 was confirmed upon its three-step transformation to lepadiformine (1). Thus, subjection of alcohol 18 to Mitsunobu conditions smoothly effected cyclization to the *trans*-perhydroquinoline 2 (and its separable C(13) epimer in 78% and 5% yields, respectively), whose tosyl group could be removed using standard conditions to provide amine 19. Treatment of amine **19** with iodine in ether $(-40 \text{ }^{\circ}\text{C} \text{ to room temperature, 1 h})$ gave rise to an (iodomethyl)pyrrolidinium salt that was concentrated and directly taken up in THF and aqueous NaOH containing 10% tetrabutylammonium iodide to deliver racemic lepadiformine (77%). This transformation presumably proceeds through regioselective attack of hydroxide on the aziridinium ion intermediate 20.21 We could not detect any product derived from ring opening at the more substituted site (cf. cylindricines A and B). The spectral properties of

⁽¹³⁾ In contrast to other examples of 2-amidoacrolein Diels–Alder cycloaddition reactions performed in our laboratories,^{5h} the cycloaddition of 2-tosylamidoacrolein **6** could not be accomplished under thermal conditions as a result of competing polymerization of dienophile **6** (150 °C). In addition, the acid sensitivity of the acetal functionality of diene **7** precluded the use of Lewis acid catalysts.

⁽¹⁴⁾ Weinreb, S. M. Top. Curr. Chem. 1997, 190, 131.

⁽¹⁵⁾ For the preparation of the parent system by DIBAL-H reduction of *N*-tosylcaprolactam to afford the corresponding α -hydroxytosylamide and further transformation to the α -methoxytosylamide by treatment with methanol, trimethyl orthoformate, and PPTS, see: Åhman, J.; Somfai, P. *Tetrahedron* **1992**, *48*, 9537.

⁽¹⁶⁾ Fleming, I.; Dunoguès, J.; Smithers, R. Org. React. 1989, 37, 57.

⁽¹⁷⁾ Smith, J. G.; Drozda, S. E.; Petraglia, S. P.; Quinn, N. R.; Rice, E. M.; Taylor, B. S.; Viswanathan, M. J. Org. Chem. **1984**, *49*, 4112.

⁽¹⁸⁾ In a competition experiment, (3-hexenyl)trimethylsilane was preferentially consumed over allyltrimethylsilane by trifluoroacetic acid (¹H NMR).

^{(19) (}a) Molander, G. A.; Burkhardt, E. R.; Weinig, P. J. Org. Chem. **1990**, 55, 4990. (b) Molander, G. A.; Estévez-Braun, A. M. Bull. Soc. Chim. Fr. **1997**, 134, 275. (c) For a very recent example of the utility of these reagents, see: Johnston, D.; Francon, N.; Edmonds, J. J.; Procter, D. J. Org. Lett. **2001**, 3, 2001.

⁽²⁰⁾ Kibayashi also invokes chelation control in the stereoselective addition of hexylmagnesium bromide (2.0:1) to a spirocyclic aldehyde similar to 16 that possesses a Cbz-protected alkoxypyrrolidine ring; see ref 5a.

⁽²¹⁾ For a related example, see: Guo-qiang, L.; Chun-min, A.; Zhi-cai, S. *Heterocycles* **1995**, *41*, 277.

compound **1** were identical to those reported by Kibayashi and the spectra of the hydrochloride salt of **1** were indistinguishable from those of authentic material.²²

In conclusion, we have completed a stereoselective total synthesis of the cytotoxin (\pm)-lepadiformine in 16 steps in 13% overall yield from ethyl sorbate. Moreover, we have once again demonstrated that amidoacrolein-derived Diels-Alder cycloadducts can be easily elaborated to the ring systems of tricyclic alkaloids. The further development and

application of this methodology in natural product synthesis is underway.

Acknowledgment. We appreciate the financial support provided by the National Institutes of Health (GM28553).

Supporting Information Available: Spectroscopic data and experimental details for the preparation of all new compounds. This material is available free of charge via the Internet at http://pubs.acs.org.

OL0165903

⁽²²⁾ We thank Professor Weinreb for sharing Professor J. F. Biard's authentic ¹H and ¹³C NMR spectra of lepadiformine with us. For their approach to lepadiformine, see the accompanying communication in this issue: Sun, P.; Sun, C.; Weinreb, S. M. *Org. Lett.* **3**, 3507–3510.